Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting
Adicet Bio (NASDAQ: ACET) announced two poster presentations for its ADI-270 therapy at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting in San Diego. The first presentation will showcase preclinical data comparing ADI-270, an armored allogeneic anti-CD70 γδ CAR T cell therapy, to conventional αβ CAR benchmarks in terms of efficacy and safety. The second presentation will detail a Phase 1/2 first-in-human study of ADI-270 in patients with relapsed or refractory clear cell renal cell carcinoma (ccRCC). The presentations are scheduled for March 12 and 13, 2025, respectively.
Adicet Bio (NASDAQ: ACET) ha annunciato due presentazioni in formato poster per la sua terapia ADI-270 al prossimo Incontro Scientifico Primaverile della Society for Immunotherapy of Cancer (SITC) 2025 a San Diego. La prima presentazione metterà in evidenza dati preclinici che confrontano ADI-270, una terapia con cellule T CAR γδ anti-CD70 allogeniche armate, con i benchmark convenzionali delle cellule T CAR αβ in termini di efficacia e sicurezza. La seconda presentazione fornirà dettagli su uno studio di Fase 1/2 in prima linea sull'uomo di ADI-270 in pazienti con carcinoma renale a cellule chiare (ccRCC) in recidiva o refrattario. Le presentazioni sono programmate per il 12 e 13 marzo 2025.
Adicet Bio (NASDAQ: ACET) anunció dos presentaciones de póster para su terapia ADI-270 en la próxima Reunión Científica de Primavera de la Society for Immunotherapy of Cancer (SITC) 2025 en San Diego. La primera presentación mostrará datos preclínicos que comparan ADI-270, una terapia con células T CAR γδ anti-CD70 alogénica armada, con los estándares convencionales de células T CAR αβ en términos de eficacia y seguridad. La segunda presentación detallará un estudio de Fase 1/2 en humanos de ADI-270 en pacientes con carcinoma renal de células claras (ccRCC) en recaída o refractario. Las presentaciones están programadas para el 12 y 13 de marzo de 2025.
Adicet Bio (NASDAQ: ACET)는 샌디에고에서 열리는 2025년 봄 과학 회의 암 면역 요법 학회(SITC)에서 ADI-270 치료에 대한 두 개의 포스터 발표를 발표했습니다. 첫 번째 발표에서는 ADI-270, 즉 무장된 동종 이식 항-CD70 γδ CAR T 세포 치료의 효능과 안전성을 기존의 αβ CAR 기준과 비교한 전임상 데이터를 소개합니다. 두 번째 발표에서는 재발 또는 난치성 투명 세포 신장 세포 암(ccRCC) 환자에 대한 ADI-270의 1/2상 첫 인간 연구를 상세히 설명합니다. 발표는 각각 2025년 3월 12일과 13일로 예정되어 있습니다.
Adicet Bio (NASDAQ: ACET) a annoncé deux présentations d'affiches pour sa thérapie ADI-270 lors de la prochaine Réunion Scientifique de Printemps de la Society for Immunotherapy of Cancer (SITC) 2025 à San Diego. La première présentation mettra en avant des données précliniques comparant ADI-270, une thérapie par cellules T CAR γδ anti-CD70 allogéniques armées, aux références conventionnelles des cellules T CAR αβ en termes d'efficacité et de sécurité. La deuxième présentation détaillera une étude de Phase 1/2 chez l'homme de l'ADI-270 chez des patients atteints de carcinome rénal à cellules claires (ccRCC) en rechute ou réfractaire. Les présentations sont prévues pour les 12 et 13 mars 2025.
Adicet Bio (NASDAQ: ACET) gab bekannt, dass zwei Posterpräsentationen zu seiner Therapie ADI-270 auf dem bevorstehenden Frühjahrswissenschaftlichen Treffen der Society for Immunotherapy of Cancer (SITC) 2025 in San Diego stattfinden werden. Die erste Präsentation wird präklinische Daten vorstellen, die ADI-270, eine gepanzerte allogene anti-CD70 γδ CAR-T-Zelltherapie, mit konventionellen αβ CAR-Benchmarks hinsichtlich Wirksamkeit und Sicherheit vergleichen. Die zweite Präsentation wird eine Phase-1/2-Studie an Menschen mit rezidiviertem oder refraktärem klarzelligem Nierenzellkarzinom (ccRCC) detailliert beschreiben. Die Präsentationen sind für den 12. und 13. März 2025 geplant.
- Preclinical data shows ADI-270 has improved efficacy and safety vs conventional treatments
- Advancement to Phase 1/2 clinical trials for renal cell carcinoma
- None.
Details of the poster presentation are as follows:
Abstract Title: ADI-270, an Armored Allogeneic Anti-CD70 γδ CAR T Cell Therapy, Demonstrates Improved Efficacy and Safety in Preclinical Models Compared to Conventional αβ CAR Benchmarks
Poster/Abstract Number: 39
Presenting Author: Shon Green, Ph.D.
Date/Time: Wednesday, March 12, 2025, from 5:10 p.m. – 6:45 p.m. PT
Abstract Title: A Phase 1/2 First in Human Study of ADI-270, an Armored Allogeneic Anti-CD70 Chimeric Antigen Receptor γδ T Cell Therapy, in Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma (ccRCC)
Poster/Abstract Number: 136
Presenting Author: Gregory Vosganian, M.D.
Date/Time: Thursday, March 13, 2025, from 5:00 p.m. – 6:30 p.m. PT
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250303266774/en/
Adicet Bio, Inc.
Investor and Media Contacts
Investors:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Media:
Kerry Beth Daly
kbdaly@adicetbio.com
Source: Adicet Bio, Inc.
FAQ
What is ADI-270 and how does it differ from conventional CAR T therapies?
What type of cancer is being targeted in Adicet Bio's (ACET) Phase 1/2 trial of ADI-270?
When will Adicet Bio (ACET) present the ADI-270 data at SITC 2025?
What are the abstract numbers for Adicet Bio's (ACET) ADI-270 presentations at SITC 2025?
